Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
A weight-loss drug more effective than Ozempic and Wegovy has recently been approved. Here’s how it works and how it compares ...
Rapper Fat Joe recently shared how he’s been using the Type 2 diabetes medication Ozempic to maintain his 200-pound weight ...
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Medicare coverage of the drugs would up federal spending by $35 billion from 2026 to 2034. Meanwhile, CNBC tests Abbott’s ...
One of the biggest changes takes effect in 2025. Part D drug plans must cap out-of-pocket spending on covered drugs at $2,000 ...
New weight-loss jabs could help boost the economy in Britain by getting people “back into work”, the Prime Minister has said. Sir Keir Starmer said that the anti-obesity medication could also help ...
A study by Health Innovation Manchester and Lilly will examine the “real-world effectiveness” of anti-obesity treatment Mounjaro, also known as tirzepatide, on weight loss, diabetes prevention, the ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...